骨扫描指数作为乳腺癌骨转移患者预后工具的评价。

IF 1.5 4区 医学 Q3 PHARMACOLOGY & PHARMACY Current radiopharmaceuticals Pub Date : 2023-01-01 DOI:10.2174/1874471016666230509113108
Maria Silvia De Feo, Viviana Frantellizzi, Arianna Di Rocco, Alessio Farcomeni, Antonio Matto, Andrea Marongiu, Susanna Nuvoli, Angela Spanu, Giuseppe De Vincentis
{"title":"骨扫描指数作为乳腺癌骨转移患者预后工具的评价。","authors":"Maria Silvia De Feo,&nbsp;Viviana Frantellizzi,&nbsp;Arianna Di Rocco,&nbsp;Alessio Farcomeni,&nbsp;Antonio Matto,&nbsp;Andrea Marongiu,&nbsp;Susanna Nuvoli,&nbsp;Angela Spanu,&nbsp;Giuseppe De Vincentis","doi":"10.2174/1874471016666230509113108","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Bone metastatic involvement represents a leading cause of death in patients with advanced breast cancer (BC). At present, it is not clear whether the bone metastatic load might impact Overall Survival (OS) in patients with bone metastatic BC at diagnosis. For this purpose, we used the Bone Scan Index (BSI), which is a reproducible and quantitative expression of tumor load observed at bone scintigraphy.</p><p><strong>Objective: </strong>The aim of this study was to associate BSI with OS in bone metastatic BC patients.</p><p><strong>Methods: </strong>In this retrospective study, we enrolled BC patients with bone metastases at the scintigraphic bone scan performed for staging purposes. The BSI was calculated through the DASciS software, and statistical analysis was carried out. Other clinical variables relevant to OS analysis were taken into account.</p><p><strong>Results: </strong>Of a total of 94 patients, 32% died. In most cases, the histotype was ductal infiltrating carcinoma. The median OS from diagnosis was 72 months (CI 95%: 62-NA). The univariate analysis with COX regression showed that only hormone therapy significantly correlates with OS (HR 0.417, CI 95%: 0.174-0.997, p < 0.049). As concerning BSI, the statistical analysis showed that it does not predict OS in BC patients (HR 0.960, 95% CI: 0.416-2.216, p < 0.924).</p><p><strong>Conclusion: </strong>Although the BSI significantly predicts OS in prostate cancer and in other tumors, we observed that the metastatic load of bone disease has not a key role in prognostic stratification in our population.</p>","PeriodicalId":10991,"journal":{"name":"Current radiopharmaceuticals","volume":"16 4","pages":"284-291"},"PeriodicalIF":1.5000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Evaluation of Bone Scan Index as a Prognostic Tool in Breast Cancer Patients with Bone Metastasis.\",\"authors\":\"Maria Silvia De Feo,&nbsp;Viviana Frantellizzi,&nbsp;Arianna Di Rocco,&nbsp;Alessio Farcomeni,&nbsp;Antonio Matto,&nbsp;Andrea Marongiu,&nbsp;Susanna Nuvoli,&nbsp;Angela Spanu,&nbsp;Giuseppe De Vincentis\",\"doi\":\"10.2174/1874471016666230509113108\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Bone metastatic involvement represents a leading cause of death in patients with advanced breast cancer (BC). At present, it is not clear whether the bone metastatic load might impact Overall Survival (OS) in patients with bone metastatic BC at diagnosis. For this purpose, we used the Bone Scan Index (BSI), which is a reproducible and quantitative expression of tumor load observed at bone scintigraphy.</p><p><strong>Objective: </strong>The aim of this study was to associate BSI with OS in bone metastatic BC patients.</p><p><strong>Methods: </strong>In this retrospective study, we enrolled BC patients with bone metastases at the scintigraphic bone scan performed for staging purposes. The BSI was calculated through the DASciS software, and statistical analysis was carried out. Other clinical variables relevant to OS analysis were taken into account.</p><p><strong>Results: </strong>Of a total of 94 patients, 32% died. In most cases, the histotype was ductal infiltrating carcinoma. The median OS from diagnosis was 72 months (CI 95%: 62-NA). The univariate analysis with COX regression showed that only hormone therapy significantly correlates with OS (HR 0.417, CI 95%: 0.174-0.997, p < 0.049). As concerning BSI, the statistical analysis showed that it does not predict OS in BC patients (HR 0.960, 95% CI: 0.416-2.216, p < 0.924).</p><p><strong>Conclusion: </strong>Although the BSI significantly predicts OS in prostate cancer and in other tumors, we observed that the metastatic load of bone disease has not a key role in prognostic stratification in our population.</p>\",\"PeriodicalId\":10991,\"journal\":{\"name\":\"Current radiopharmaceuticals\",\"volume\":\"16 4\",\"pages\":\"284-291\"},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current radiopharmaceuticals\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2174/1874471016666230509113108\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current radiopharmaceuticals","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/1874471016666230509113108","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

背景:骨转移累及是晚期乳腺癌(BC)患者死亡的主要原因。目前尚不清楚骨转移负荷是否会影响骨转移性BC患者诊断时的总生存期(OS)。为此,我们使用骨扫描指数(Bone Scan Index, BSI),这是在骨扫描中观察到的肿瘤负荷的可重复和定量表达。目的:本研究的目的是将骨转移性BC患者的BSI与OS联系起来。方法:在这项回顾性研究中,我们招募了在骨扫描中进行分期的骨转移的BC患者。通过DASciS软件计算BSI,并进行统计分析。其他与OS分析相关的临床变量也被考虑在内。结果:94例患者中,32%死亡。大多数病例的组织类型为导管浸润性癌。诊断后的中位OS为72个月(CI 95%: 62-NA)。单因素COX回归分析显示,只有激素治疗与OS显著相关(HR 0.417, CI 95%: 0.174 ~ 0.997, p < 0.049)。BSI不能预测BC患者的OS (HR 0.960, 95% CI: 0.416-2.216, p < 0.924)。结论:尽管BSI可以显著预测前列腺癌和其他肿瘤的OS,但我们观察到骨病的转移负荷在我们的人群中并不是预后分层的关键作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Evaluation of Bone Scan Index as a Prognostic Tool in Breast Cancer Patients with Bone Metastasis.

Background: Bone metastatic involvement represents a leading cause of death in patients with advanced breast cancer (BC). At present, it is not clear whether the bone metastatic load might impact Overall Survival (OS) in patients with bone metastatic BC at diagnosis. For this purpose, we used the Bone Scan Index (BSI), which is a reproducible and quantitative expression of tumor load observed at bone scintigraphy.

Objective: The aim of this study was to associate BSI with OS in bone metastatic BC patients.

Methods: In this retrospective study, we enrolled BC patients with bone metastases at the scintigraphic bone scan performed for staging purposes. The BSI was calculated through the DASciS software, and statistical analysis was carried out. Other clinical variables relevant to OS analysis were taken into account.

Results: Of a total of 94 patients, 32% died. In most cases, the histotype was ductal infiltrating carcinoma. The median OS from diagnosis was 72 months (CI 95%: 62-NA). The univariate analysis with COX regression showed that only hormone therapy significantly correlates with OS (HR 0.417, CI 95%: 0.174-0.997, p < 0.049). As concerning BSI, the statistical analysis showed that it does not predict OS in BC patients (HR 0.960, 95% CI: 0.416-2.216, p < 0.924).

Conclusion: Although the BSI significantly predicts OS in prostate cancer and in other tumors, we observed that the metastatic load of bone disease has not a key role in prognostic stratification in our population.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Current radiopharmaceuticals
Current radiopharmaceuticals PHARMACOLOGY & PHARMACY-
CiteScore
3.20
自引率
4.30%
发文量
43
期刊最新文献
Enhancing Ketoprofen Solubility: A Strategic Approach Using Solid Dispersion and Response Surface Methodology. Preclinical Aspects of [89Zr]Zr-DFO-Rituximab: A High Potential Agent for Immuno-PET Imaging. Apigenin's Influence on Inflammatory and Epigenetic Responses in Rat Lungs After Radiotherapy. An Analysis of the Radiosensitiser Applications in the Biomedical Field. Left Ventricular Wall Motion as an Additional Valuable Parameter in Diabetic Patients with Normal Myocardial Perfusion Imaging.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1